Business
Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nGraphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that information about the company’s Phase 1/2 CEDAR trial of GPH101, an investigational therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD), will be presented during a poster session at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. The meeting will take place virtually and at the Georgia World Congress Center in Atlanta from December 11-14.\n\nThe ASH abstract is now available at www.hematology.org. Details of the Graphite Bio poster presentation are as follows:\n\nPoster Session: 801. Gene Therapies: Poster I\nPoster #1864: CEDAR Trial in Progress: A First in Human, Phase 1/2 Study of the Correction of a Single Nucleotide Mutation in Autologous HSCs (GPH101) to Convert HbS to HbA for Treating Severe SCD\nPresenting Author: Julie Kanter, M.D., University of Alabama at Birmingham\nDate and Time: Saturday, Dec. 11, 9 a.m.-7:30 p.m. ET\n\nAbout Sickle Cell Disease (SCD)\n\nSCD is a serious, life-threatening inherited blood disorder that affects approximately 100,000 people in the United States and millions of people around the world, making it the most prevalent monogenic disease worldwide. SCD is caused by a single mutation in the beta-globin gene that leads red blood cells to become misshapen, resulting in anemia, blood flow blockages, intense pain, increased risk of stroke and organ damage, and reduced life expectancy of approximately 20-30 years. Despite advancements in treatment and care, progressive organ damage continues to cause early mortality and severe morbidity, highlighting the need for curative therapies.\n\nAbout GPH101\n\nGPH101 is an investigational next-generation gene-edited autologous hematopoietic stem cell (HSC) therapy designed to directly correct the genetic mutation that causes sickle cell disease (SCD). GPH101 is the first investigational therapy to use a highly differentiated gene correction approach that seeks to efficiently and precisely correct the mutation in the beta-globin gene to decrease sickle hemoglobin (HbS) production and restore normal adult hemoglobin (HbA) expression, ther...